Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Generation Bio (GBIO) Accounts Payables (2021 - 2025)

Historic Accounts Payables for Generation Bio (GBIO) over the last 5 years, with Q3 2025 value amounting to $2.1 million.

  • Generation Bio's Accounts Payables rose 2441.23% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 2441.23%. This contributed to the annual value of $1.4 million for FY2024, which is 3998.29% down from last year.
  • Latest data reveals that Generation Bio reported Accounts Payables of $2.1 million as of Q3 2025, which was up 2441.23% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Generation Bio's Accounts Payables registered a high of $2.6 million during Q3 2023, and its lowest value of $296000.0 during Q1 2021.
  • Its 5-year average for Accounts Payables is $1.6 million, with a median of $1.7 million in 2024.
  • Examining YoY changes over the last 5 years, Generation Bio's Accounts Payables showed a top increase of 42263.51% in 2022 and a maximum decrease of 6727.63% in 2022.
  • Quarter analysis of 5 years shows Generation Bio's Accounts Payables stood at $2.0 million in 2021, then tumbled by 67.28% to $662000.0 in 2022, then soared by 254.38% to $2.3 million in 2023, then tumbled by 39.98% to $1.4 million in 2024, then surged by 46.59% to $2.1 million in 2025.
  • Its Accounts Payables stands at $2.1 million for Q3 2025, versus $2.2 million for Q2 2025 and $2.3 million for Q1 2025.